NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on March 11, 2024, it received two letters from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”), one notifying the Company (the “MVLS Notice”) that for the last 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “Market Value Standard”), and the other notifying the Company (the “MVPHS Notice”) that for the last 30 consecutive business days, the Company’s Market Value of Publicly Held Shares (“MVPHS”) was below the minimum of $15 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Standard”).

Continued here:
Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

FINANCIERE DE TUBIZE SA/NV

Link:
Financière de Tubize - Annual report 2023

Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors

Read the original post:
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Ad hoc announcement pursuant to Art. 53 LR

Read more:
Idorsia and Viatris successfully close the transaction for the global research and development collaboration

Saint-Herblain (France), March 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an agreement with funds managed by leading U.S. healthcare investment firms Deerfield Management Company and OrbiMed to extend the interest-only period of its existing loan by eighteen months.

See the article here:
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL:

Original post:
Arbutus to Participate in Two Upcoming Investor Conferences

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.

View original post here:
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

See the article here:
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has streamlined its executive leadership to further focus on advancing the Company’s clinical programs while optimizing resource allocation. As part of this effort, Senior Vice President, Chief Commercial Officer, Robert Francomano and Executive Vice President, General Counsel and Corporate Secretary, Barbara Wood, will be departing the Company.

Continue reading here:
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024

Here is the original post:
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug’s downstream pharmacological effects in the brain in early AD

Read the rest here:
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early...

WINNIPEG, Manitoba, March 08, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the Bioscience Association of Manitoba (“BAM”) annual awards dinner held on March 7, 2024, Kane Biotech received the BAM Company of the Year award.

Read this article:
Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award

Montrouge, France, March 8, 2024

Go here to read the rest:
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles

Read more here:
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of...

The competitive Department of Defense “Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Translational Research Award” will fund preclinical development of Biosplice’s DYRK inhibitors in traumatic brain injury (TBI) models The competitive Department of Defense “Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Translational Research Award” will fund preclinical development of Biosplice’s DYRK inhibitors in traumatic brain injury (TBI) models

See the article here:
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program

Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy® based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD).

Follow this link:
Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Evn, a pioneering company in the hemp industry, has just announced the launch of its groundbreaking product – Hemp-derived Live Resin Gummies. Each pouch is bursting with 20 wild strawberry-flavored gummies, precisely dosed with 10 mg of hemp-derived THC and 5 mg of CBD. Sourcing from a single strain - 'Sour Space Candy', a well-known hybrid, provides an elevated experience that’s both legal and luxuriously flavorful.

Read the original here:
Evn Introduces a Game-Changer in Cannabis Edibles with New Hemp-Derived Live Resin Gummies

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 AM ET in Miami, Florida.

Go here to read the rest:
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Joins exclusive group of innovative companies headquartered on Technion Campus Joins exclusive group of innovative companies headquartered on Technion Campus

See original here:
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

TAMPA, Fla., March 08, 2024 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, announced today that it will proceed with a 1-for-44 reverse stock split (the “Reverse Split”) of its issued and outstanding shares of common stock, par value $0.001, following authorization by its Board of Directors and majority shareholders to effect a reverse stock split by a ratio of not less than 1-for-25 and not more than 1-for-45 (the “Reverse Split Range”), at any time on or before March 31, 2024, with the Board having the discretion as to whether or not the Reverse Split is to be effected, and the exact ratio to be set at a whole number within the Reverse Split Range.

See the original post:
Better Choice Company To Effectuate a Reverse Stock Split